A concerned mom is warning about a New York bill that would require children to get the HPV vaccine before they could attend school. Under S298/A2912, a child would have to get the vaccine to be able to attend public school or daycare. “There’s definitely a large concern among the moms I know about this.” Laura Greenaway is a mom of two girls. She learned of the bill from posts on her Facebook feed, and now she wants to alert other moms. “It created concern and anxiety for me that this is not a decision that I can make for my own child,” Greenaway said. She doesn't believe kids should be required to be vaccinated against human papillomavirus across New York State, and Greenaway is not anti-vaccine. “My children are all up to date on other vaccines that are tried, tested and true. This is a newer vaccine with very alarming side effects,” she said.
Has the Gardasil HPV Vaccine Really Eliminated Cervical Cancer in Australia? Statistics Show Increase of Cancer Rates After Vaccine Introduced
In our September 18th debate for Spectrum TV, Kaiser’s Chief of Pediatrics, Dr. Robert Riewerts, parroted Pharma’s popular canard that the Gardasil vaccine has eliminated cervical cancer in Australia—the first country to mandate the jab. This is false. Gardasil actually increases the risk of cervical cancer by a terrifying 44.6% among women who were exposed to HPV infection prior to vaccination. If anyone ever bullies you to take Gardasil, look up “Gardasil Vaccine Insert” on your cell phone to see all of the adverse events and show them this table.
On September 28, 2019, The Daily Mail published an article titled "Now give every ADULT the cancer-fighting HPV vaccination and save 'thousands of lives', experts demand as evidence shows the jab can slash the cancer risk for grown-ups too." The article states that leading HPV expert and president of the International Papillomavirus Society, Professor Margaret Stanley, OBE, told reporters that there was a spike in the incidence of HPV cancers when people entered their 60s because their immune systems became weaker over time. She stated: "HPV breaks the usual rules of vaccination. Vaccinating older, infected people will make it less likely that cancers will develop." However, Health Impact News found no evidence to support her claim. In fact, according to our information, if a person is already infected with the HPV virus, getting vaccinated could, in fact, increase, not decrease their chances of getting cancer. In 2018, we reported that according to the research of French oncologist Dr. Gérard Delépine, the HPV vaccine Gardasil was actually associated with an increased rate of cervical cancer among patients. If Dr. Delépine’s research is correct, then if everyone in Britain were to be vaccinated with the HPV vaccine, there is an extremely high possibility that the rates for cervical cancer in Britain could increase.
Finnish Citizens Conduct Own Vaccine Safety Study and Question Health Authorities Letting 12-Year-Olds Make Own Decisions About HPV Vaccine without Parental Consent
A support group comprised of vaccine-injured and their families in Finland circulated an internet-based questionnaire to find out if there could be an association between vaccinations and healthy children or adolescents/adults falling ill. Once the results were compiled and analyzed, it was impossible for them to find a medical professional willing to help them get the results published in a peer-reviewed medical journal. They contacted academics from their own country and abroad. All of those contacts agreed that the study has been conducted well and that it deserved to be published, but none of them were willing to co-author the manuscript because of the controversial nature of the topic. In other words, they were afraid of being bullied and losing their position. "How ethical is it to give the HPV-vaccine without informed consent and to advertise it is safe and effective and leave the decision to 12 years old girls?"
This story started when my daughter Chiara was 13 years old, now she is 18. She used to be a very good athlete with symptoms from Hashimoto’s thyroiditis with high levels of anti-thyroid peroxidase antibodies. These were already known much before receiving the HPV vaccine. She was really a good athlete and Hashimoto’s did not stop her from participating in the World Championship Karate in Caorle where she had the first place twice. In 2010, she took the brown belt. Apart from Karate interest, Chiara’s other hobbies included painting, singing and practicing all kind of sports. That was Chiara’s profile before Gardasil. Six years have already passed since the Gardasil treatment and the strong headache, dizziness, osteochondritis, Hashimoto’s, articular and abdominal pains are still there. Moreover, she is still under a strict diet that prevents her from taking milk derivatives and food containing gluten. This is my daughter’s story and I wrote it to bring you about the injuries that Gardasil could cause. I hope our experience could help any of you to make the best decision and deeply investigate before subject your son to any HPV vaccine. Above all, I hope Chiara and all the other survivors of new medical conditions after HPV vaccinations find treatments to help them get their normal lives back.
The CDC is a major player in the vaccine marketplace, buying half of all childhood vaccines in the U.S. and then selling them to contracted public health agencies through the Vaccines for Children (VFC) Program, which pushes free and low-cost vaccines on indigent children. Over the past three decades, the CDC’s vaccine purchases have increased 15-fold as the average cost of fully vaccinating a child to age 18 rose from $100 to $2192—while vaccine companies have raked in the profits. The agency’s involvement with vaccine manufacturers also extends to patents, licensing agreements and collaboration on projects to develop new vaccines. In fact, the CDC and the National Institutes of Health (NIH) profit handsomely from their ownership or co-ownership with private sector partners of vaccine-related patents. Some of the key technologies underlying the development of the HPV vaccines Gardasil and Cervarix emerged from research patented by the NIH’s National Cancer Institute (NCI), which then licensed the technology to Merck, MedImmune and GlaxoSmithKline. By 2009, HPV licensing had become NIH’s top generator of royalty revenues. Gardasil is “perhaps the leading example of a new form of unconstrained government self-dealing, in arrangements whereby [HHS] can transfer technology to pharmaceutical partners, [and] simultaneously both approve and protect their partners’ technology licenses while also taking a cut of the profits.” It seems doubtful that agencies can remain impartial in the face of these profits.
It has been 13 years since the U.S. Food and Drug Administration (FDA) supplied fast-tracked approval for Merck’s Gardasil vaccine—promoted for the prevention of cervical cancer and other conditions attributed to four types of human papillomavirus (HPV). The agency initially licensed Gardasil solely for 9- to 26-year-old girls and women, but subsequent FDA decisions now enable Merck to market Gardasil’s successor—the nine-valent Gardasil 9 vaccine—to a much broader age range—9 to 45 years—and to both males and females. As a result of Gardasil’s expanding markets not just in the U.S. but internationally, the blockbuster HPV vaccine has become Merck’s third highest-grossing product, bringing in annual global revenues of about $2.3 billion. However, Gardasil’s safety record has been nothing short of disastrous. Children’s Health Defense and Robert F. Kennedy, Jr. have just produced a video detailing the many problems with the development and safety of Gardasil. What follow are 25 key facts about Gardasil/Gardasil 9, including facts about the HPV vaccines’ clinical trials and adverse outcomes observed ever since Merck, public health officials and legislators aggressively foisted the vaccines on an unsuspecting public.
New Research: High HPV Cancer Rates Linked to High Gardasil Vaccination Rates – “Exactly the Opposite of what we Expected”
Last year (2018) we reported on the research of French oncologist Dr. Gérard Delépine, who published an analysis of the HPV vaccine Gardasil showing how increased rates of Gardasil vaccinations are actually correlated with a higher rate of cervical cancer. Now, researchers at the University of South Alabama are observing the same link of increased Gardasil vaccination rates with an increased rate of HPV related cervical cancers in Alabama. The researchers and medical doctors commented that this was a "surprising discovery" and that it was "exactly the opposite of what we expected." It is highly unlikely this will be reported in any of the corporate-sponsored "mainstream" media sources.
Robert F. Kennedy, Jr. is one of the attorneys in the Jennifer Robi vs. Merck and Kaiser Permanente fraud case currently being litigated in Los Angeles Superior Court. This must-watch video, referencing much of the science presented as evidence during the trial, details the many problems with the development and safety of Merck’s third-highest grossing product, Gardasil. Children’s Health Defense (CHD) and Robert F. Kennedy, Jr., CHD’s Chairman and Chief Legal Counsel, ask that you watch and share this video so that you, and others, may make an informed decision of whether or not to give your child, boy or girl, a Gardasil vaccine. It can also be a useful tool for pediatricians who are trying to understand how this vaccine, that is actually causing health problems with young people, could have been approved by FDA and then recommended by CDC. The video is full of jaw-dropping facts about Gardasil and the clinical trials leading up to its release upon an unsuspecting public.
Merck Sees “Unprecedented” Growth in Gardasil Vaccine – Over $3 Billion in Sales in 2018 with Expansion into China
Vaccine manufacturer Merck & Co. has reported earnings from its Gardasil HPV vaccine for 2018 at $3.15 billion, far above the previous year sales of $2.31 billion. First quart of 2019 sales of the Gardasil vaccine have soared 31% to $838 million for the first three months of 2019. Executives from the company have stated that these sales of the Gardasil vaccine are "unprecedented," and the company plans to spend over $1 billion to expand its Gardasil vaccine production. Much of this growth of the Gardasil vaccine market is due to Merck's expansion into China. While many other countries, like Japan, are pulling back on their recommendations for the Gardasil vaccines due to the sheer volume of reported Gardasil vaccine injuries, and the resulting lawsuits in those countries against Merck and its distributors, something that is not possible in the United States due to the legal immunity vaccine makers enjoy, China is running full speed ahead to introduce the Gardasil vaccine to its population.